Clinical update of MCLA-129 presented at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
– Zenocutuzumab (Zeno) Regulatory update: FDA recommends additional enrollment in eNRGy trial to support potential BLA filing– Clinical update of petosemtamab planned for first half of 2023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.